81,813 Shares in Avantor, Inc. $AVTR Acquired by Lazard Asset Management LLC

Lazard Asset Management LLC acquired a new position in shares of Avantor, Inc. (NYSE:AVTR) during the 1st quarter, HoldingsChannel.com reports. The firm acquired 81,813 shares of the company’s stock, valued at approximately $641,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in AVTR. EverSource Wealth Advisors LLC raised its position in shares of Avantor by 119.1% during the second quarter. EverSource Wealth Advisors LLC now owns 2,187 shares of the company’s stock worth $29,000 after acquiring an additional 1,189 shares during the last quarter. Private Trust Co. NA boosted its holdings in Avantor by 46.2% in the fourth quarter. Private Trust Co. NA now owns 2,769 shares of the company’s stock valued at $32,000 after acquiring an additional 875 shares during the last quarter. Strategic Wealth Investment Group LLC bought a new position in Avantor in the second quarter valued at about $32,000. Los Angeles Capital Management LLC bought a new stake in Avantor during the 4th quarter worth about $32,000. Finally, Osaic Holdings Inc. raised its holdings in Avantor by 60.9% during the 2nd quarter. Osaic Holdings Inc. now owns 2,810 shares of the company’s stock worth $38,000 after purchasing an additional 1,064 shares during the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently issued reports on AVTR. Barclays raised their target price on shares of Avantor from $7.00 to $8.00 and gave the company an “underweight” rating in a research note on Wednesday, June 24th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $13.00 price objective on shares of Avantor in a report on Thursday, July 30th. Citigroup raised their price objective on shares of Avantor from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Wednesday, July 8th. Zacks Research raised shares of Avantor from a “strong sell” rating to a “hold” rating in a report on Thursday, April 30th. Finally, Sanford C. Bernstein began coverage on shares of Avantor in a research report on Friday, June 26th. They set a “market perform” rating and a $10.50 target price for the company. Two investment analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $12.00.

Avantor Stock Performance

Shares of NYSE:AVTR opened at $13.21 on Friday. The firm’s 50 day simple moving average is $10.66 and its 200 day simple moving average is $9.47. Avantor, Inc. has a fifty-two week low of $7.26 and a fifty-two week high of $15.93. The company has a market capitalization of $8.93 billion, a price-to-earnings ratio of -15.72, a P/E/G ratio of 10.06 and a beta of 0.89. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.78 and a quick ratio of 1.18.

Avantor (NYSE:AVTR) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.02. Avantor had a negative net margin of 8.81% and a positive return on equity of 9.92%. The firm had revenue of $1.69 billion during the quarter, compared to analysts’ expectations of $1.61 billion. During the same quarter in the previous year, the company earned $0.24 earnings per share. The business’s revenue for the quarter was up .5% on a year-over-year basis. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. As a group, sell-side analysts forecast that Avantor, Inc. will post 0.81 earnings per share for the current year.

Avantor Company Profile

Avantor, Inc (NYSE:AVTR) is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor’s offerings are organized across two primary segments.